

Microba Life Sciences Limited (ASX: MAP)

27 June 2025

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES

SHARE PURCHASE PLAN INVITATION

Dear Shareholder,

We are pleased to invite you to participate in Microba Life Sciences Limited's (**Microba** or **the Company**) Share Purchase Plan (**SPP**). This is an opportunity to invest in the Company at the same price as institutional investors who participated in the \$12.5m institutional placement (**Placement**). In the SPP, Microba is raising \$2.0 million to drive expanded clinical adoption of the Company's core microbiome testing products. Microba is in a key growth phase driving towards regional break-even milestones, and your support through this capital raise will help us realise health outcomes for more patients and value creation for shareholders.

Why Participate?

- Buy at \$0.09 per share the same price as the Placement, with no brokerage or fees
- Free attaching options 1 for every 2 shares, exercisable at \$0.14 for 2 years post-issue
- Flexible investment sizes from \$2,000 minimum to \$30,000 maximum
- Support Microba's growth proceeds fund key growth initiatives and drive towards regional break-even milestones

This letter is to notify you that the SPP is now open and to provide you with instructions as to how to obtain a copy of the Prospectus and your personalised application form to apply for New Shares and New Options under the SPP (Application Form).

Offer Summary

On 23 June 2025, Microba Life Sciences Limited announced that it was undertaking a fully underwritten Share Purchase Plan to raise up to \$2.0 million.

Under the SPP, Eligible Shareholders will be able to apply for new ordinary shares in the Company (**New Share**) at an issue price of \$0.09 per New Share up to a maximum of \$30,000 worth of New Shares, with one free attaching option for every two New Shares issued, exercisable at \$0.14 per Option on or before the date that is two years following their issue (**New Option**), without paying any brokerage fees, being the same price to be paid by participants in the \$12.5 million Placement announced by Microba on 23 June 2025.

Eligibility

You are eligible to participate if you:

- held Microba ordinary shares at 7.00pm (AEST) on 20 June 2025 (Record Date);
- had a registered address in Australia or New Zealand at the Record Date; and
- are not located in the United States, and are not acting for the account or benefit of persons in the United States.

Eligible Shareholders may apply for New Shares in the following increments, from a minimum of \$2,000 up to a maximum of \$30,000 as detailed below:

Offer	SPP Investment Amount	Number of New Shares	Number of free New Options
Offer A	\$30,000	333,333	166,666
Offer B	\$25,000	277,777	138,888





Offer C	\$20,000	222,222	111,111
Offer D	\$15,000	166,666	83,333
Offer E	\$10,000	111,111	55,555
Offer F	\$7,500	83,333	41,666
Offer G	\$5,000	55,555	27,777
Offer H	\$2,000	22,222	11,111

Participation in the SPP is entirely voluntary. If applications exceed the targeted amount of \$2.0 million, the Company will scale back allocations on a pro-rata basis (having regard to the applicant's shareholding) to ensure the total amount raised does not exceed \$2.0 million. Decisions are made by the Board in consultation with the Joint Lead Managers and Underwriters, Morgans Corporate Limited and Canaccord Genuity (Australia) Limited, and are final. In the case of a scale back, an Eligible Shareholder may receive less New Shares than they applied for. Should this occur, Microba will refund any excess application funds, without interest.

The SPP is being made under prospectus issued under section 713 of the *Corporations Act 2001* (Cth) (**Prospectus**) and is subject to the terms and conditions set out in the Prospectus (**Terms and Conditions**). By lodging an Application for New Shares (and attaching New Options) under the Prospectus for the SPP, you agree to be bound by the Terms and Conditions.

How to participate

Eligible Shareholders can download a personalised Application Form, Prospectus and Target Market Determination from the Automic Investor Portal.

If you require any assistance with accessing these documents, please call the Share Registry, Automic on 1300 288 664 (from within Australia) or +61 2 9698 5414 (from outside Australia) or email corporate.actions@automicgroup.com.au and ask for a copy of the Application Form, Prospectus and Target Market Determination to be provided via email or post, free of charge. Please note, you will need to provide your HIN or SRN and postcode to complete this request.

Details on how to apply are provided below:

I already have an online account with the Automic Share Registry	I don't have an online account with Automic and wish to register for one	I don't have an online account with Automic – but wish to use Automic for this Offer only
https://investor.automic.com.au Select: "Existing Users Sign In".	https://investor.automic.com.au/#/signup	https://investor.automic.com.au/ #/loginsah
Once you have successfully signed in, click on "Documents and Statements".	Select Microba Life Sciences Limited from the dropdown list in the ISSUER field.	Select Microba Life Sciences Limited from the dropdown list in the ISSUER field.
Download the Prospectus, Target Market Determination and Application Form.	Enter your holder number SRN / HIN (from your latest Holding Statement). Enter a single	Enter your holder number SRN / HIN (from your latest Holding Statement). Enter a single
Submit your payment using the payment details provided on your personalised Application Form.	identifying word from your holder name. Enter your Postcode (Australia) or Country of Residence	identifying word from your holder name. Enter your Postcode (Australia) or Country
Do not return your Application Form.	(Outside Australia). Tick box "I am not a robot", then next Complete the prompts.	of Residence (Outside Australia). Tick box "I am not a robot", then next Complete the prompts.
	Once you have successfully signed in, click on "Documents and Statements".	Once you have successfully signed in, click on "Documents



JOIN MICROBA'S INTERACTIVE INVESTOR HUB

For more Company information and to engage with management by asking questions about Microba's latest announcements and updates, visit **ir.microba.com/welcome**



and Statements". Download the Prospectus, Target Market Determination and Download the Prospectus, Application Form. **Target Market Determination** and Application Form. Submit your payment using the payment details provided on your Submit your payment using the personalised Application Form. payment details provided on your personalised Application Do not return your Application Form. Form. Do not return your Application Form.

Please note that there may be delays in the delivery of the Prospectus and your personalised Application Form via post. The Company takes no responsibility for any late delivery of the Prospectus and strongly encourages you to apply in accordance with the Application Form.

The SPP is scheduled to close at 5:00pm (AEST) on Wednesday, 6 August 2025 (Closing Date). Your Application Form and payment in accordance with the Application Form must be received before this time.

You should read the Prospectus and Target Market Determination carefully and in their entirety before deciding whether to participate in the SPP. Microba strongly advises that you seek advice from your stockbroker, solicitor, accountant or other professional advisor to determine if this investment is suitable for you.

Key Dates¹

The key dates with respect to the SPP, are detailed below:

Record Date	7:00pm, Friday, 20 June 2025
Announcement of fully underwritten SPP	Monday, 23 June 2025
Lodgement of Prospectus with ASIC and ASX	Friday, 27 June 2025
Despatch of Prospectus	Friday, 27 June 2025
Opening Date of SPP	Friday, 27 June 2025
Closing Date for SPP ¹	Wednesday, 6 August 2025
General Meeting	Friday, 8 August 2025
Issue of New Shares and New Options under the SPP (as approved at the General Meeting)	Wednesday, 13 August 2025
Despatch of Holding Statements for the New Shares and New Options under the SPP	Thursday, 14 August 2025
Trading commences for New Shares under the SPP	Thursday, 14 August 2025

⁽¹⁾ Microba reserves the right to close the SPP earlier than this date or extend the SPP for longer.





General Meeting

The issue of New Shares and New Options under the SPP is subject to Shareholder approval being obtained at the general meeting proposed to be held on Friday, 8 August 2025 (**General Meeting**). No New Options will be issued pursuant to the SPP until such time as Shareholder approval has been obtained.

Action required by Eligible Shareholders to participate in the SPP:

- Australian residents: Pay via BPAY or direct transfer (EFT)
- New Zealand residents: Pay via direct transfer (EFT)

All payments must be made in Australian dollars and received by the SPP closing date of **5:00pm** (**AEST**) on **Wednesday**, **6 August 2025**. Microba may close or extend the SPP at its discretion.

Participation in the SPP is optional and Eligible Shareholders may elect to do nothing. If you do nothing, you will continue to hold the same number of shares in Microba, however, your interest in Microba will be further diluted. Your right to participate in the SPP is not transferable.

Stay Informed — Join the Microba Investor Hub

To ensure you're receiving timely company email updates, ASX announcements & invitations to investor webinars, we encourage all shareholders to activate their Microba Investor Hub profile.

With your Microba Investor Hub profile, you can:

- · Access company news, market updates and ASX announcements
- Stay informed about exclusive investor webinars and events
- · Engage directly with the Microba team through Q&A

Activate your profile today at https://ir.microba.com/ or simply scan the QR code.



If you have any questions in relation to the SPP or other Investor Relations queries, please contact the Company via email at investor@microba.com.

Thank you for your continued support of Microba. We are excited about the opportunities ahead and invite you to participate in this Share Purchase Plan as we expand clinical adoption and deliver long-term value for shareholders.

Yours sincerely,

Pasquale Rombola

Chair | Microba Life Sciences Limited

Authorised for release by The Board of Directors

